Alan Richard Burns

Title: Alan Richard Burns: Innovator in Isoindolinone Inhibitors

Introduction

Alan Richard Burns is a notable inventor based in Loughborough, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of isoindolinone inhibitors that target the MDM2-P53 interaction. His work has implications for cancer treatment and drug development.

Latest Patents

Alan Richard Burns holds one patent titled "Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them." This invention relates to processes for preparing isoindolin-1-one derivatives, specifically focusing on the compound (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. The patent also covers crystalline forms of this compound and its salts.

Career Highlights

Throughout his career, Alan has worked with prominent companies in the pharmaceutical sector. He has been associated with Astex Therapeutics Limited and Cancer Research Technology Limited, where he has contributed to innovative research and development projects.

Collaborations

Alan Richard Burns has collaborated with notable professionals in his field, including Steven Howard and Jeffrey David St Denis. These collaborations have enhanced his research and contributed to advancements in cancer therapeutics.

Conclusion

Alan Richard Burns is a distinguished inventor whose work in isoindolinone inhibitors has the potential to impact cancer treatment significantly. His contributions to the pharmaceutical industry reflect his dedication to innovation and research.